Management of the well renal transplant recipient: Outpatient surveillance and treatment recommendations

Seminars in Dialysis

Volumn 18, Issue 6, 2005, Pages 520-528

  Salifu, Moro O ^a   Tedla, Fasika ^a   Markell, Mariana S ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; OUTPATIENT; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; REVIEW;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; OUTPATIENTS; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE;

EID: 30744475211     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.00099.x     Document Type: Review

References (86)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998
2. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7:158-165, 1996
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988-1996. N Engl J Med 342:605-612, 2000
4. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int 57:307-313, 2000
5. Wheeler DC, Steiger J: Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 70:S41-S45, 2000
6. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC, International Expert Panel: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75(10 suppl):S3-S24, 2003
7. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors. a systematic review and meta-analysis. Am J Transplant 4:583-595, 2004
8. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: β-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71:1417-1423, 2001
9. Hathaway DK, Tolley EA, Blakely ML, Winsett RP, Gaber AO: Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 7:330-338, 1993
10. Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P: Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 61:1475-1478, 1996
11. Sumrani NB, Delaney V, Ding Z, Davis R, Daskalakis P, Friedman EA, Butt KM, Hong JH: Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 51:343-347, 1991
12. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3:178-185, 2003
13. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 5:1374-1380, 2002
14. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11(suppl 15):S1-S86, 2000
15. Grinyo JM, Cruzado JM: Steroid or calcineurin inhibitor-sparing immunosuppressive protocols. Contrib Nephrol 146:30-42, 2005
16. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11:1910-1917, 2000
17. Abouljoud MS, Kumar MS, Brayman KL, Emre S, Bynon JS, OLN-452 Study Group: Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 16:168-172, 2002
18. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53:217-222, 1998
19. de Vries AP, Bakker SJ, van Son WJ, van der Heide JJH, Ploeg RJ, Hauw TT, de Jong PE, Gans ROB: Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 4:1675-1683, 2004
20. Morales JM, Andres A, Rengel M, Rodicio JL: Influence of cyclosporine, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 16(suppl 1):121-124, 2001
21. Koomans HA, Ligtenberg G: Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 72:S9-S12, 2001
22. Patel NH, Jindal RM, Wilkin T, Rose S, Johnson MS, Shah H, Namyslowski J, Moresco KP, Trerotola SO: Renal arterial stenosis in renal allografts: retrospective study of predisposing factors and outcome after percutaneous transluminal angioplasty. Radiology 219:663-667, 2001
23. Bruno S, Remuzzi G, Ruggenenti P: Transplant renal artery stenosis. J Am Soc Nephrol 15:134-141, 2004
24. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE: Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 6:521-530, 2000
25. Devlin J, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C: Renal complications and development of hypertension in the European study of FK 506 and cyclosporine in primary liver transplant recipients. Transpl Int 7(suppl 1):S22-S26, 1994
26. Mange KC, Cizman B, Joffe M, Feldman HI: Arterial hypertension and renal allograft survival. JAMA 283:633-638, 2000
27. EBPG Expert Group on Renal Transplantation: European best practice guidelines for renal transplantation. Section IV. Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant 17(suppl 4):25-26, 2002
28. Park JM, Luan FL: Management of hypertension in solid-organ transplantation. Prog Transplant 15:17-22, 2005
29. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
30. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32:S142-S156, 1998
31. Sugahara S, Koyama I, Yoshikawa Y, Dohi Y, Omoto R: Lipid and lipoprotein(a) in renal transplant recipients. Transplant Proc 26:2080-2081, 1994
32. Sharma AK, Myers TA, Hunninghake DB, Matas AJ, Kashtan CE: Hyperlipidemia in long-term survivors of pediatric renal transplantation. Clin Transplant 8:252-257, 1994
33. Aakhus S, Dahl K, Wideroe TE: Hyperlipidaemia in renal transplant patients. J Intern Med 239:407-415, 1996
34. Gisbert C, Prieto M, Berenguer M, Breto M, Carrasco D, de Juan M, Mir J, Berenguer J: Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 3:416-422, 1997
35. Baum CL: Weight gain and cardiovascular risk after organ transplantation. JPEN J Parenter Enteral Nutr 25:114-119, 2001
36. Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S: Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75:1213-1220, 2003
37. Hernandez D, Alvarez A, Torres A, Oppenheimer F, Cobo M, Gonzalez-Posada J, Jimenez A, Lorenzo V, Torregrosa V: Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 35:1727-1729, 2003
38. Massy ZA: Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation 72(6 suppl):S13-S15, 2001
39. Castello IB: Hyperlipidemia: a risk factor for chronic allograft dysfunction. Kidney Int Suppl 80:73-77, 2002
40. Roodnat JI, Mulder PG, Zietse R, Rischen-Vos J, van Riemsdijk IC, Ijzermans JN, Weimar W: Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 69:1704-1710, 2000
41. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, Wilson PW: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4(suppl 7):13-53, 2004
42. National Heart, Lung, and Blood Institute: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at http://www.nhlbi.nih.gov/ guidelines/cholesterol/
43. Bostom AG, Gohh RY, Beaulieu AJ, Han H, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Transplantation 68:257-261, 1999
44. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson CL: Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 131:331-339, 1999
45. Ducloux D, Ruedin C, Gibey R, Vautrin P, Bresson-Vautrin C, Rebibou JM, Chalopin JM: Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Nephrol Dial Transplant 13:2890-2893, 1998
46. Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG: Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2:308-313, 2002
47. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995
48. Shafik IM, Quamme GA: Early adaptation of renal magnesium reabsorption in response to magnesium restriction. Am J Physiol 257:F974-F977, 1989
49. Quamme GA: Renal magnesium handling: new insights in understanding old problems. Kidney Int 52:1180-1195, 1997
50. Markell MS, Altura BT, Sarn Y, Barbour R, Friedman EA, Altura BM: Relationship of ionized magnesium and cyclosporine level in renal transplant recipients. Ann NY Acad Sci 696:408-411, 1993
51. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, Grenda R, Janda J, Hughes D, Ehrich JH, Klare B, Zacchello G, Bjorn Brekke I, McGraw M, Perner F, Ghio L, Balzar E, Friman S, Gusmano R, Stolpe J: Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 17:141-149, 2002
52. Ramos EL, Barri YM, Kubilis P, Peterson JC, Pfaff WW, Howard RJ, Parris CJ, Patton PR, Karlix JL: Hypomagnesemia in renal transplant patients: improvement over time and association with hypertension and cyclosporine levels. Clin Transplant 9:185-189, 1995
53. Vannini SD, Mazzola BL, Rodoni L, Truttmann AC, Wermuth B, Bianchetti MG, Ferrari P: Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 12:244-249, 1999
54. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S: Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem 238:163-179, 2002
55. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
56. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: the Framingham study. Am Heart J 108:1347-1352, 1984
57. Fishman JA, Rubin RH: Infection in organ-transplant recipients. N Engl J Med 338:1741-1751, 1998
58. Davis CL: The prevention of cytomegalovirus disease in renal transplantation. Am J Kidney Dis 16:175-188, 1990
59. Jamil B, Nicholls KM, Becker GJ, Walker RG: Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Clin Transplant 14:14-18, 2000
60. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611-620, 2004
61. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE: Infection in the renal transplant recipient. Am J Med 70:405-411, 1981
62. Moyses Neto M, Costa RS, Reis MA, Ferraz AS, Saber LT, Batista ME, Muglia V, Garcia TM, Figueiredo JF: Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transplant 11(5 pt 1):446-452, 1997
63. Singh N, Paterson DL: Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 27:1266-1277, 1998
64. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM: Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 14:456-463, 1999
65. Torres A, Lorenzo V, Salido E: Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13:551-558, 2002
66. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11:1093-1099, 2000
67. Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R: Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int 55:2021-2029, 1999
68. Sperschneider H, Stein G: Bone disease after renal transplantation. Nephrol Dial Transplant 18:874-877, 2003
69. Clive DM: Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 11:974-979, 2000
70. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, Zarraga S, Calabozo M, Herrero-Beites AM, Nolla J: Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant 18:603-606, 2003
71. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 4:905-913, 2004
72. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534, 1999
73. Mix TC, Kazmi W, Khan S, Ruthazer R, Rohrer R, Pereira BJ, Kausz AT: Anemia: a continuing problem following kidney transplantation. Am J Transplant 3:1426-1433, 2003
74. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F: Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 3:835-845, 2003
75. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG: Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 14:214-221, 1995
76. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173-192, 1988
77. Izzedine H, Launay-Vacher V, Baumelou A, Deray G: Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 66:532-541, 2004
78. Kaplan B, Meier-Kriesche HU, Jacobs MG, Friedman G, Bonomini L, DeFranco P, Gelfand E, Mulgaonkar S: Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis 34:65-68, 1999
79. Vega KJ, Pina I, Krevsky B: Heart transplantation is associated with an increased risk for pancreaticobiliary disease. Ann Intern Med 124:980-983, 1996
80. Mueller XM, Tevaearai HT, Stumpe F, Hurni M, Ruchat P, Fischer AP, Seydoux C, Goy JJ, von Segesser LK: Gastrointestinal disease following heart transplantation. World J Surg 23:650-655, 1999; discussion 655-656
81. Patel N, Salifu M, Sumrani N, Distant D, Hong J, Markell M, Braverman AS: Successful treatment of post-renal transplant Kaposi's sarcoma with paclitaxel. Am J Transplant 2:877-879, 2002
82. Raiz L, Davies EA, Ferguson RM: Sexual functioning following renal transplantation. Health Soc Work 28:264-272, 2003
83. De Celis R, Pedron-Nuevo N: Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive regimen. Arch Androl 42:9-20, 1999
84. Barrou B, Cuzin B, Malavaud B, Petit J, Pariente JL, Buchler M, Cormier L, Benoit G, Costa P: Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 18:411-417, 2003
85. First MR, Combs CA, Weiskittel P, Miodovnik M: Lack of effect of pregnancy on renal allograft survival or function. Transplantation 59:472-476, 1995
86. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378-383, 2004